Idenix
Announces
13
Abstracts
on
Hepatitis
B and
C Accepted
for
the
2006
Annual
Meeting
of
the
European
Association
for
the
Study
of
the
Liver
(EASL)
Idenix
Pharmaceuticals
announced
this
week
that
13
of
its
submitted
abstracts
on
therapy
for
chronic
hepatitis
B and
hepatitis
C have
been
accepted
for
presentation
at
the
41st
annual
meeting
of
the
European
Association
for
the
Study
of
the
Liver
(EASL),
to
be
held
in
Vienna,
Austria,
April
26-30,
2006.
Telbivudine
is
an
investigational
compound
for
the
treatment
of
hepatitis
B.
Idenix
is
currently
evaluating
telbivudine
in
an
ongoing
two-year
international
phase
III
clinical
trial
referred
to
as
the
GLOBE
study.
The
GLOBE
study,
in
which
1,367
patients
are
enrolled,
is
comparing
600
mg
dose
of
telbivudine
orally
administered
once
a day
to
treatment
once
a day
with
100
mg
of
lamivudine.
The
most
frequently
reported
adverse
events
in
the
GLOBE
study
were
upper
respiratory
tract
infection,
nasopharyngitis,
fatigue
and
headache.
Creatine
kinase
(CK)
elevations,
not
requiring
treatment
modification,
were
more
common
among
patients
treated
with
telbivudine
compared
to
lamivudine.
EASL
Abstracts
on
Telbivudine
Idenix
is
developing
its
hepatitis
B product
candidates
in
collaboration
with
Novartis
Pharma
AG
under
a license
granted
by
Idenix
and
a development
and
commercialization
arrangement
established
in
May
2003.
Stefan
Zeuzem,
Professor
of
Medicine
at
Saarland
University,
in
Homburg,
Germany,
will
present
"Optimal
Virologic
and
Clinical
Efficacy
at
One
Year
is
Associated
with
Maximal
Early
HBV
Suppression
in
Nucleoside-Treated
Hepatitis
B Patients"
in
a meeting
session
on
Friday,
April
28
at
5:15
p.m.
CET.
Henry
Chan,
Associate
Professor
of
Medicine
at
the
Chinese
University
of
Hong
Kong,
will
present
"A
Randomized
Trial
of
Telbivudine
(LdT)
vs.
Adefovir
for
HBeAg-Positive
Chronic
Hepatitis
B:
Results
of
the
Primary
Week
24
Analysis"
in
a meeting
session
on
Friday,
April
28
at
5:30
p.m.
CET.
Satawat
Thongsawat,
Professor
of
Medicine
at
Chiang
Mai
University
in
Thailand,
will
present
"Telbivudine
Displays
Consistent
Antiviral
Efficacy
Across
Patient
Subgroups
for
the
Treatment
of
Chronic
Hepatitis
B:
Results
from
the
GLOBE
Study"
in
a meeting
session
on
Sunday,
April
30
at
1:15
p.m.
CET.
Nikolai
Naoumov,
Consultant
Physician
at
the
Institute
of
Hepatology,
University
College
London,
England,
will
present
"Effect
of
Core
Promoter/Precore
Mutation
Pattern
and
Early
Virologic
Response
on
Efficacy
Outcomes
with
Telbivudine
in
HBeAg-negative
Chronic
Hepatitis
B"
in
the
poster
session
beginning
on
Thursday
April
27,
2006
at
7:00
p.m.
CET.
Edward
Gane,
Associate
Professor
of
Gastroenterology
and
Hepatology
at
Middlemore
Hospital
in
Auckland,
New
Zealand,
will
present
"Phase
III
Comparison
of
Telbivudine
vs.
Lamivudine
in
HBeAg-Positive
Patients
with
Chronic
Hepatitis
B:
Efficacy,
Safety,
and
Predictors
of
Response
at
1 Year"
in
the
poster
session
beginning
on
Thursday,
April
27,
2006
at
7:00
p.m.
CET.
Xiao-Jian
Zhou
will
present
"Absence
of
Pharmacokinetic
Drug-Drug
Interaction
Between
Telbivudine
and
Peginterferon
alfa-2a
or
Cyclosporine
in
Healthy
Subjects"
in
the
poster
session
beginning
on
Thursday,
April
27,
2006
at
7:00
p.m.
CET.
David
Standring,
Idenix's
Senior
Vice
President,
Biology,
will
present
"HBV
Resistance
Determination
from
the
Telbivudine
GLOBE
Registration
Trial"
in
the
poster
session
beginning
on
Thursday,
April
27,
2006
at
7:00
p.m.
CET.
Edward
Bridges,
Idenix's
Vice
President,
Preclinical
Pharmacology
and
Toxicology,
will
present
"Telbivudine
Preclinical
Safety
Studies
Suggest
Minimal
Risk
of
Chronic
Toxicity,
Reproductive
Toxicity
or
Carcinogenicity"
in
the
poster
session
beginning
on
Thursday,
April
27,
2006
at
7:00
p.m.
CET.
03/31/06
Sources
PRNewswire-FirstCall.
Idenix
Announces
Thirteen
Data
Presentations
at
the
2006
European
Association
for
the
Study
of
the
Liver.
March
27,
2006.
http://www.idenix.com.
|
